Benefit finding and caregiving burden among primary caregivers of patients with advanced cancer in China: A latent profile analysis
Asia-Pacific Journal of Oncology Nursing · 2026-12 · 13 · 100969
DOI: 10.1016/j.apjon.2026.100969 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asia-Pacific Journal of Oncology Nursing, 2026-12. Verfasst von Xue Jin und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Nursing, Anhui Medical University, Hefei, China. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Anhui Medical University.
Abstract (Originalsprache)
Objective
This study aimed to identify latent profiles of benefit finding (BF) among primary caregivers of patients with advanced cancer in China, examine factors associated with these profiles, and explore the association between BF profiles and caregiving burden.
Methods
In this cross-sectional study, 365 primary caregivers of patients with advanced cancer were recruited from a tertiary hospital in Hefei, China, using convenience sampling. Data were collected using a sociodemographic and disease-related information questionnaire, the revised Benefit Finding Scale, and the Caregiver Burden Scale for Cancer Patients. Descriptive statistics, latent profile analysis, and multivariate logistic regression were used for data analysis, and multiple linear regression was used to examine the association between BF profiles and caregiving burden.
Results
Three latent profiles of BF were identified: "low benefit-lack of self-awareness" (51.2%), "moderate benefit-natural acceptance" (33.7%), and "high benefit-personal and family growth together" (15.1%). Caregivers' age, educational level, monthly per capita household income, caregiving experience, the presence of co-caregivers, and relationship to the patient were significantly associated with BF profile membership (P < 0.05). After adjustment for confounding factors, caregivers in the "moderate benefit-natural acceptance" profile reported significantly lower caregiving burden than those in the "low benefit-lack of self-awareness" profile (P < 0.05).
Conclusions
BF among primary caregivers of patients with advanced cancer in China is heterogeneous and can be categorized into three latent profiles. Caregivers in the "moderate benefit-natural acceptance" profile report lower caregiving burden. Health care providers may develop targeted interventions based on the characteristics and associated factors of different BF profiles to help alleviate caregiving burden.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Nursing, Anhui Medical University, Hefei, China.
- Department of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
- Outpatient Operating Room II, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Förderung
- Anhui Medical University
Zitieren
APA
Jin, X., Wang, Y., Wu, S., Zhang, Z., Zhao, S., Liu, L., Lu, X., Zheng, L., Wang, Z., Lv, Y., Lei, Y., & Du, H. (2026). Benefit finding and caregiving burden among primary caregivers of patients with advanced cancer in China: A latent profile analysis. Asia-Pacific Journal of Oncology Nursing, 13, 100969. https://doi.org/10.1016/j.apjon.2026.100969
Vancouver
Jin X, Wang Y, Wu S, Zhang Z, Zhao S, Liu L, et al. Benefit finding and caregiving burden among primary caregivers of patients with advanced cancer in China: A latent profile analysis. Asia-Pacific Journal of Oncology Nursing. 2026;13:100969. doi:10.1016/j.apjon.2026.100969
BibTeX
@article{Jin2026,
author = {Jin, Xue and Wang, Yuejia and Wu, Shengwu and Zhang, Zixuan and Zhao, Shuchi and Liu, Lamei and Lu, Xiangyu and Zheng, Lingling and Wang, Zuochuan and Lv, Yin and Lei, Yingge and Du, Hua},
title = {Benefit finding and caregiving burden among primary caregivers of patients with advanced cancer in China: A latent profile analysis},
journal = {Asia-Pacific Journal of Oncology Nursing},
year = {2026},
volume = {13},
pages = {100969},
doi = {10.1016/j.apjon.2026.100969}
}
EUVIMED